MOUNJARO Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Mounjaro, and when can generic versions of Mounjaro launch?
Mounjaro is a drug marketed by Eli Lilly And Co and is included in one NDA. There are two patents protecting this drug.
This drug has one hundred and ten patent family members in forty-four countries.
The generic ingredient in MOUNJARO is tirzepatide. One supplier is listed for this compound. Additional details are available on the tirzepatide profile page.
DrugPatentWatch® Generic Entry Outlook for Mounjaro
Mounjaro will be eligible for patent challenges on May 13, 2026. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be January 5, 2036. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
Summary for MOUNJARO
International Patents: | 110 |
US Patents: | 2 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 3 |
Clinical Trials: | 1 |
Drug Prices: | Drug price information for MOUNJARO |
What excipients (inactive ingredients) are in MOUNJARO? | MOUNJARO excipients list |
DailyMed Link: | MOUNJARO at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for MOUNJARO
Generic Entry Date for MOUNJARO*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
SOLUTION;SUBCUTANEOUS |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for MOUNJARO
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Eli Lilly and Company | Phase 4 |
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center | Phase 4 |
Pharmacology for MOUNJARO
Anatomical Therapeutic Chemical (ATC) Classes for MOUNJARO
US Patents and Regulatory Information for MOUNJARO
MOUNJARO is protected by two US patents and one FDA Regulatory Exclusivity.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of MOUNJARO is ⤷ Try a Trial.
This potential generic entry date is based on patent ⤷ Try a Trial.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting MOUNJARO
GIP/GLP1 agonist compositions
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
GIP and GLP-1 co-agonist compounds
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: MOUNJARO IS INDICATED AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
FDA Regulatory Exclusivity protecting MOUNJARO
NEW CHEMICAL ENTITY
Exclusivity Expiration: ⤷ Try a Trial
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Eli Lilly And Co | MOUNJARO (AUTOINJECTOR) | tirzepatide | SOLUTION;SUBCUTANEOUS | 215866-005 | May 13, 2022 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Eli Lilly And Co | MOUNJARO (AUTOINJECTOR) | tirzepatide | SOLUTION;SUBCUTANEOUS | 215866-004 | May 13, 2022 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
Eli Lilly And Co | MOUNJARO (AUTOINJECTOR) | tirzepatide | SOLUTION;SUBCUTANEOUS | 215866-005 | May 13, 2022 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Eli Lilly And Co | MOUNJARO (AUTOINJECTOR) | tirzepatide | SOLUTION;SUBCUTANEOUS | 215866-004 | May 13, 2022 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Eli Lilly And Co | MOUNJARO | tirzepatide | SOLUTION;SUBCUTANEOUS | 215866-007 | Jul 28, 2023 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
Eli Lilly And Co | MOUNJARO | tirzepatide | SOLUTION;SUBCUTANEOUS | 215866-012 | Jul 28, 2023 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
EU/EMA Drug Approvals for MOUNJARO
Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
---|---|---|---|---|---|---|---|---|---|
Eli Lilly Nederland B.V. | Mounjaro | tirzepatide | EMEA/H/C/005620 Mounjaro is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise- as monotherapy when metformin is considered inappropriate due to intolerance or contraindications- in addition to other medicinal products for the treatment of diabetes.For study results with respect to combinations, effects on glycaemic control and the populations studied, see sections 4.4, 4.5 and 5.1. |
Authorised | no | no | no | 2022-09-15 | |
>Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for MOUNJARO
When does loss-of-exclusivity occur for MOUNJARO?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Argentina
Patent: 3242
Estimated Expiration: ⤷ Try a Trial
Australia
Patent: 16205435
Estimated Expiration: ⤷ Try a Trial
Brazil
Patent: 2017010596
Estimated Expiration: ⤷ Try a Trial
Canada
Patent: 73352
Estimated Expiration: ⤷ Try a Trial
Chile
Patent: 17001760
Estimated Expiration: ⤷ Try a Trial
China
Patent: 7207576
Estimated Expiration: ⤷ Try a Trial
Patent: 2608377
Estimated Expiration: ⤷ Try a Trial
Colombia
Patent: 17006737
Estimated Expiration: ⤷ Try a Trial
Costa Rica
Patent: 170310
Estimated Expiration: ⤷ Try a Trial
Croatia
Patent: 0191614
Estimated Expiration: ⤷ Try a Trial
Denmark
Patent: 42887
Estimated Expiration: ⤷ Try a Trial
Dominican Republic
Patent: 017000153
Estimated Expiration: ⤷ Try a Trial
Ecuador
Patent: 17043648
Estimated Expiration: ⤷ Try a Trial
El Salvador
Patent: 17005453
Estimated Expiration: ⤷ Try a Trial
Eurasian Patent Organization
Patent: 1591
Estimated Expiration: ⤷ Try a Trial
Patent: 5055
Estimated Expiration: ⤷ Try a Trial
Patent: 1791281
Estimated Expiration: ⤷ Try a Trial
Patent: 1892057
Estimated Expiration: ⤷ Try a Trial
Patent: 2090392
Estimated Expiration: ⤷ Try a Trial
European Patent Office
Patent: 42887
Estimated Expiration: ⤷ Try a Trial
Patent: 97662
Estimated Expiration: ⤷ Try a Trial
Finland
Patent: 0230005
Estimated Expiration: ⤷ Try a Trial
France
Patent: C1006
Estimated Expiration: ⤷ Try a Trial
Hungary
Patent: 45860
Estimated Expiration: ⤷ Try a Trial
Patent: 300006
Estimated Expiration: ⤷ Try a Trial
Israel
Patent: 2499
Estimated Expiration: ⤷ Try a Trial
Patent: 6492
Estimated Expiration: ⤷ Try a Trial
Patent: 1545
Estimated Expiration: ⤷ Try a Trial
Japan
Patent: 19534
Estimated Expiration: ⤷ Try a Trial
Patent: 45766
Estimated Expiration: ⤷ Try a Trial
Patent: 54867
Estimated Expiration: ⤷ Try a Trial
Patent: 17507124
Estimated Expiration: ⤷ Try a Trial
Patent: 18052933
Estimated Expiration: ⤷ Try a Trial
Patent: 19203000
Estimated Expiration: ⤷ Try a Trial
Jordan
Patent: 0200119
Estimated Expiration: ⤷ Try a Trial
Patent: 75
Estimated Expiration: ⤷ Try a Trial
Lithuania
Patent: 2023504
Estimated Expiration: ⤷ Try a Trial
Patent: 42887
Estimated Expiration: ⤷ Try a Trial
Malaysia
Patent: 3616
Estimated Expiration: ⤷ Try a Trial
Mexico
Patent: 17008927
Estimated Expiration: ⤷ Try a Trial
Patent: 21005835
Estimated Expiration: ⤷ Try a Trial
Moldova, Republic of
Patent: 42887
Estimated Expiration: ⤷ Try a Trial
Montenegro
Patent: 494
Estimated Expiration: ⤷ Try a Trial
Morocco
Patent: 315
Estimated Expiration: ⤷ Try a Trial
Patent: 422
Estimated Expiration: ⤷ Try a Trial
Netherlands
Patent: 1217
Estimated Expiration: ⤷ Try a Trial
New Zealand
Patent: 2000
Estimated Expiration: ⤷ Try a Trial
Patent: 8274
Estimated Expiration: ⤷ Try a Trial
Norway
Patent: 23005
Estimated Expiration: ⤷ Try a Trial
Peru
Patent: 170954
Estimated Expiration: ⤷ Try a Trial
Philippines
Patent: 017501252
Estimated Expiration: ⤷ Try a Trial
Poland
Patent: 42887
Estimated Expiration: ⤷ Try a Trial
Portugal
Patent: 42887
Estimated Expiration: ⤷ Try a Trial
Serbia
Patent: 146
Estimated Expiration: ⤷ Try a Trial
Singapore
Patent: 201705603Y
Estimated Expiration: ⤷ Try a Trial
Slovenia
Patent: 42887
Estimated Expiration: ⤷ Try a Trial
South Africa
Patent: 1703930
Estimated Expiration: ⤷ Try a Trial
South Korea
Patent: 1957620
Estimated Expiration: ⤷ Try a Trial
Patent: 2330764
Estimated Expiration: ⤷ Try a Trial
Patent: 170092661
Estimated Expiration: ⤷ Try a Trial
Patent: 190026967
Estimated Expiration: ⤷ Try a Trial
Patent: 210145311
Estimated Expiration: ⤷ Try a Trial
Patent: 230023822
Estimated Expiration: ⤷ Try a Trial
Spain
Patent: 47928
Estimated Expiration: ⤷ Try a Trial
Taiwan
Patent: 82109
Estimated Expiration: ⤷ Try a Trial
Patent: 1636362
Estimated Expiration: ⤷ Try a Trial
Tunisia
Patent: 17000198
Estimated Expiration: ⤷ Try a Trial
Ukraine
Patent: 8239
Estimated Expiration: ⤷ Try a Trial
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering MOUNJARO around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Israel | 252499 | תרכובות קו-אגוניסטיות ל- gip ו- glp-1 (Gip and glp-1 co-agonist compounds) | ⤷ Try a Trial |
Argentina | 103242 | COMPUESTOS CO-AGONISTAS DE GIP Y GLP-1 | ⤷ Try a Trial |
China | 112312926 | GIP/GLP1激动剂组合物 (GIP/GLP1 AGONIST COMPOSITIONS) | ⤷ Try a Trial |
Mexico | 2020013727 | COMPOSICIONES AGONISTAS DE GIP/GLP1. (GIP/GLP1 AGONIST COMPOSITIONS.) | ⤷ Try a Trial |
Poland | 3242887 | ⤷ Try a Trial | |
New Zealand | 732000 | Gip and glp-1 co-agonist compounds | ⤷ Try a Trial |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for MOUNJARO
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
3242887 | CA 2023 00005 | Denmark | ⤷ Try a Trial | PRODUCT NAME: TIRZEPATID OG FARMACEUTISK ACCEPTABLE SALTE DERAF; REG. NO/DATE: EU/1/22/1685 20220919 |
3242887 | C03242887/01 | Switzerland | ⤷ Try a Trial | PRODUCT NAME: TIRZEPATID; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 68726 02.11.2022 |
3242887 | 122023000012 | Germany | ⤷ Try a Trial | PRODUCT NAME: TIRZEPATIDE UND PHARMAZEUTISCH AKZEPTABLE SALZE DAVON; REGISTRATION NO/DATE: EU/1/22/1685 20220915 |
3242887 | 301217 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: TIRZEPATIDE EN FARMACEUTISCH AANVAARDBARE ZOUTEN DAARVAN; REGISTRATION NO/DATE: EU/1/22/1685 20220919 |
3242887 | 2023C/506 | Belgium | ⤷ Try a Trial | PRODUCT NAME: TIRZEPATIDE; AUTHORISATION NUMBER AND DATE: EU/1/22/1685 20220919 |
3242887 | LUC00296 | Luxembourg | ⤷ Try a Trial | PRODUCT NAME: TIRZEPATIDE ET SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; AUTHORISATION NUMBER AND DATE: EU/1/22/1685 20220919 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |